Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing diabetes and other chronic conditions.
Powered by the Welldoc App, the platform offers AI-driven health coaching, self-tracking and personalised insights to improve patient outcomes.
ByramConnect is an FDA-cleared class II software as a medical device intended for patients with type 1 or type 2 diabetes. Clinical studies show that users experienced improvements in A1C levels, blood pressure and weight management. The app integrates data from fitness trackers, glucose monitors, blood pressure monitors and other connected health devices.
Key features include AI-driven digital coaching, diet and nutrition support, GLP-1 medication tracking and mental well-being guidance. Patients receive personalised health reports with actionable insights to share with their healthcare providers.
The platform is available at no additional cost exclusively to Byram Healthcare diabetes customers. Eligible users will receive email invitations with an access code to download the app on iOS and Android devices.
Johnson & Johnson's nipocalimab granted FTD for treatment of Sjogren's disease
RedHill Biopharma to submit Talicia for UK marketing authorisation
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab
Eneboparatide Shows Positive Results in Phase III Trial for Chronic Hypoparathyroidism
Precision BioSciences secures IND clearance for gene editing therapy targeting chronic hepatitis B
Xeris Biopharma secures FDA approval for Gvoke VialDx as diagnostic aid
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Femasys receives CE mark approval for FemBloc delivery system in Europe
European Commission approves Rxulti for adolescent schizophrenia treatment